Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Type I protein arginine N-methyltransferases (PRMTs), such as PRMT3, catalyze the formation of asymmetric N(G),N(G)-dimethylarginine (ADMA) residues in proteins (Tang et al., 1998 [PubMed 9642256]).[supplied by OMIM, Mar 2008].. Additionally we are shipping PRMT3 Proteins (7) and many more products for this protein.
Showing 10 out of 91 products:
Cow (Bovine) Polyclonal PRMT3 Primary Antibody for WB - ABIN2779474
Singh, Miranda, Jiang, Frankel, Roemer, Robb, Gutmann, Herschman, Clarke, Newsham: DAL-1/4.1B tumor suppressor interacts with protein arginine N-methyltransferase 3 (PRMT3) and inhibits its ability to methylate substrates in vitro and in vivo. in Oncogene 2004
Human Polyclonal PRMT3 Primary Antibody for EIA, IHC (p) - ABIN356524
Tang, Gary, Clarke, Herschman: PRMT 3, a type I protein arginine N-methyltransferase that differs from PRMT1 in its oligomerization, subcellular localization, substrate specificity, and regulation. in The Journal of biological chemistry 1998
Human Polyclonal PRMT3 Primary Antibody for ELISA, WB - ABIN4347348
Kölbel, Ihling, Bellmann-Sickert, Neundorf, Beck-Sickinger, Sinz, Kühn, Wahle: Type I Arginine Methyltransferases PRMT1 and PRMT-3 Act Distributively. in The Journal of biological chemistry 2009
PRMT3 translocation by palmitic acid is coupled to the binding of LXRalpha (show NR1H3 Antibodies), which is responsible for the onset of fatty liver.
This work profilies substrates of protein arginine N-methyltransferase 3 with S-adenosyl-L-methionine analogues.
Mutational defects in PRMT3 is not the cause of frontotemporal lobar degeneration.
results show that protein arginine methyl transferase (PRMT)-3 and -5 methylate NaV1.5 (show SCN5A Antibodies) in vitro, interact with NaV1.5 (show SCN5A Antibodies) in human embryonic kidney (HEK (show EPHA3 Antibodies)) cells, and increase NaV1.5 (show SCN5A Antibodies) current density
The crystal structure of PRMT3 in complex with an inhibitor as well as kinetic analysis reveals an allosteric site of inhibition.
release of VHL30 from the E3 ligase complex, promotes the binding of VHL30 to a protein arginine methyltransferase (show PRMT1 Antibodies), PRMT3
The Tyr87Cys and Tyr87Glu-PRMT3 variants had markedly decreased affinity to ribosomal protein S2 (show RPS2 Antibodies) and, consequently, reduced enzymatic activity compared to the wild-type enzyme.
PRMT3 is a ribosomal protein methyltransferase that affects the cellular level of ribosomal subunits.
DAL-1/4.1B (show EPB41L3 Antibodies) protein significantly inhibits PRMT3 methylation of cellular substrates, which may affect mechanism through which DAL-1/4.1B (show EPB41L3 Antibodies) affects tumor cell growth.
Type I Arginine Methyltransferases PRMT1 (show PRMT1 Antibodies) and PRMT-3 Act Distributively
The zinc-finger domain of mouse PRMT3 is necessary & sufficient for binding to human rpS2 (show RPS2 Antibodies). rpS2 (show RPS2 Antibodies) is methylated by PRMT3, implicating PRMT3 in ribosomal function & in the regulation of protein synthesis.
The present ontogenetic analysis of PRMT1 (show PRMT1 Antibodies) and PRMT3 using Western blot methodology clearly revealed that PRMT3 develops during the perinatal stage and its expression is maintained even in adulthood.
mouse embryos with a targeted disruption of PRMT3 are small in size but survive after birth and attain a normal size in adulthood, thus displaying Minute-like characteristics
Type I protein arginine N-methyltransferases (PRMTs), such as PRMT3, catalyze the formation of asymmetric N(G),N(G)-dimethylarginine (ADMA) residues in proteins (Tang et al., 1998
protein arginine N-methyltransferase 3
, protein arginine methyltransferase 3
, HMT1 hnRNP methyltransferase-like 3
, heterogeneous nuclear ribonucleoprotein methyltransferase-like protein 3
, heterogeneous nuclear ribonucleoprotein methyltransferase-like 3
, protein arginine N-methyltransferase 3(hnRNP methyltransferase S. cerevisiae)-like 3